Amastatin
| 4095-v | 0.5 mg | 48.00 EUR |
| 4095-25 | 25 mg | 745.00 EUR |
[(2S,3R)- 3- Amino- 2- Hydroxy- 5- Methyl- Hexanoyl]- L- Valyl- L- Valyl- L- Aspartic Acid
| (M.W. 474.55) | C21H38N4O8Cl | [67655-94-1] |
Synthetic Product
Amastatin is a competitive inhibitor for human Serum Aminopeptidase A, M and Leucine Aminopeptidase.
The protease inhibitors Amastatin and Leupeptin (Code 4041)
can be used in combination with EDTA for the stabilization of endogenous, biologically active peptides in plasma or serum as well as in whole blood.
Amastatin shows effects on the hydrolysis of some opioid peptides. Since Amastatin and Phosphoramidon supresses aminopeptidase actions coinjection of these inhibitors shows significant prolongation effects an vasopressin and oxytocin activities.
References:
- T. Aoyagi, H. Tobe, F. Kojima, M. Hamada, T. Takeuchi and H. Umezawa, J. Antibiotics, 31, 636 (1978)
- P.M. Dando and A.J. Barrett, Enzyme 343. Aminopeptidase PS,(A.J. Barrett, N.D. Rawlings, and J.F. Woessner eds), Academic Press, New York, (1998). (Inhibitory Activity of Amastatin)
Amastatin is distributed through Peptide Institute, Inc. under the license of Microbial Chemistry Research Foundation.
